213 filings
DEFA14A
NVCR
NovoCure Ltd
22 Apr 24
Additional proxy soliciting materials
4:02pm
DEF 14A
NVCR
NovoCure Ltd
Definitive proxy
22 Apr 24
4:00pm
PRE 14A
NVCR
NovoCure Ltd
Preliminary proxy
12 Apr 24
4:01pm
8-K
NVCR
NovoCure Ltd
27 Mar 24
Regulation FD Disclosure
7:00am
S-8
NVCR
NovoCure Ltd
22 Feb 24
Registration of securities for employees
7:11am
8-K
1d4pmjjhapq
22 Feb 24
Novocure Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update
7:06am
8-K
a06ps9
18 Jan 24
Novocure Announces FDA Acceptance of the PMA Application for TTFields Therapy in Non-Small Cell Lung Cancer
7:01am
8-K
1z51mdk9b1y22 95v
9 Jan 24
Novocure Announces Last Patient Enrolled in Phase 3 TRIDENT Trial in Newly Diagnosed Glioblastoma
7:00am
8-K
n1sitv wfox305khileg
8 Jan 24
Novocure Announces Preliminary Full Year and Fourth Quarter 2023 Net Revenues and Provides Company Update
7:10am
8-K
fdvw8ndm93e
4 Jan 24
Novocure Appoints Dr. Nicolas Leupin as Chief Medical Officer
4:10pm
8-K
htklp2pjc8ka3fj
28 Nov 23
Regulation FD Disclosure
7:30am
8-K
02qc26fnd ms
26 Oct 23
Novocure Reports Third Quarter 2023 Financial Results
7:03am
8-K
dqq7krij1dnwu8dg7
28 Aug 23
Regulation FD Disclosure
7:00am
8-K
zvkm707ura8c3i56
27 Jul 23
Novocure Reports Second Quarter 2023 Financial Results
7:03am
8-K
jgb0ztmk4sf2v 4moss
21 Jul 23
Regulation FD Disclosure
8:00am
8-K
0p8l5lq xn
8 Jun 23
Departure of Directors or Certain Officers
4:12pm
8-K
m3x8af1vdnqmh9
6 Jun 23
Regulation FD Disclosure
3:45pm